|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...1011121314151617181920...6768» |
- Trial primary completion date: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 28, 2016
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Trial primary completion date: Dec 2015 --> Jun 2017
- Enrollment closed, Trial primary completion date: Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers (clinicaltrials.gov) - Jul 28, 2016
P1, N=26, Active, not recruiting, Sponsor: Entegrion, Inc.
Trial primary completion date: Dec 2015 --> Jun 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016
- Promacta (eltrombopag) / Novartis
Trial completion, Trial primary completion date: Promacta Pregnancy Registry (clinicaltrials.gov) - Jul 25, 2016
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Sep 2016 Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2014
- dexamethasone injection / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Monotherapy: A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma (clinicaltrials.gov) - Jul 23, 2016
P2, N=0, Withdrawn, Sponsor: Boston Medical Center
Recruiting --> Completed | Trial primary completion date: Jan 2016 --> Jul 2014 N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2019 --> Apr 2016
- ||| New trial: A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (? 65 Years) With Haematologic Neoplasms (clinicaltrials.gov) - Jul 23, 2016
P=N/A, N=80, Not yet recruiting, Sponsor: Celgene Corporation
- Enrollment closed, Enrollment change: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Jul 21, 2016
P=N/A, N=19, Active, not recruiting, Sponsor: Michael A. Thompson, MD, PhD
N=30 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Apr 2019 --> Apr 2016 Recruiting --> Active, not recruiting | N=80 --> 19
- bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date: RVD Lite: Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (clinicaltrials.gov) - Jul 20, 2016
P2, N=50, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | N=80 --> 19 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial termination: RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jul 20, 2016
P2, N=37, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2015 --> Dec 2016 Withdrawn --> Terminated; Lack of Drug Supply
- ||||| Xyntha (moroctocog alfa) / Pfizer
Enrollment closed: Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII (clinicaltrials.gov) - Jul 20, 2016
P3, N=80, Active, not recruiting, Sponsor: Pfizer
Withdrawn --> Terminated; Lack of Drug Supply Recruiting --> Active, not recruiting
- |||| Trial completion, Enrollment change: HOLA: Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America (clinicaltrials.gov) - Jul 20, 2016
P4, N=5443, Completed, Sponsor: Janssen-Cilag Ltd.
Recruiting --> Active, not recruiting Recruiting --> Completed | N=8100 --> 5443
- lenalidomide / Generic mfg.
Biomarker, Trial primary completion date: Lenalidomide Maintenance Therapy for Multiple Myeloma (clinicaltrials.gov) - Jul 19, 2016
P2, N=11, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=8100 --> 5443 Trial primary completion date: Aug 2016 --> May 2016
- Trial primary completion date: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Jul 19, 2016
P2, N=30, Suspended, Sponsor: mamdouh abdulmaksoud abdulrhman
Trial primary completion date: Aug 2016 --> May 2016 Trial primary completion date: Jan 2016 --> Jan 2017
- bortezomib / Generic mfg.
Trial termination: Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients (clinicaltrials.gov) - Jul 19, 2016
P2, N=17, Terminated, Sponsor: University of Utah
Trial primary completion date: Jan 2016 --> Jan 2017 Completed --> Terminated; Lab Staff that was required left the institution, therefore accrual closed prematurely
- alisertib (MLN8237) / Puma, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 19, 2016
P2, N=50, Active, not recruiting, Sponsor: Kristie Blum
Completed --> Terminated; Lab Staff that was required left the institution, therefore accrual closed prematurely Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM (clinicaltrials.gov) - Jul 19, 2016
P2, N=30, Recruiting, Sponsor: Azienda Ospedaliera di Bolzano
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Aug 2015 --> Dec 2015
- melphalan / Generic mfg.
Trial initiation date: Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation (clinicaltrials.gov) - Jul 19, 2016
P2, N=24, Recruiting, Sponsor: Medical College of Wisconsin
Trial primary completion date: Aug 2015 --> Dec 2015 Initiation date: Mar 2016 --> Jul 2016
- Enrollment change, Trial withdrawal: Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma (clinicaltrials.gov) - Jul 19, 2016
P0, N=0, Withdrawn, Sponsor: Washington University School of Medicine
Initiation date: Mar 2016 --> Jul 2016 N=20 --> 0 | Recruiting --> Withdrawn
- | Trial completion: Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders (clinicaltrials.gov) - Jul 19, 2016
P2, N=25, Completed, Sponsor: Beth Israel Deaconess Medical Center
N=20 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients With Solid Tumors (clinicaltrials.gov) - Jul 16, 2016
P3, N=365, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ALT-801 / ImmunityBio
Enrollment change, Trial termination, Trial primary completion date: QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 15, 2016
P1/2, N=6, Terminated, Sponsor: Altor Bioscience Corporation
Active, not recruiting --> Completed N=66 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2013; Patient population did not benefit from single agent treatment.
- | dexamethasone / Generic mfg., prednisone / Generic mfg.
Enrollment closed: GIMEMA Protocol ITP0207: Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Jul 15, 2016
P3, N=150, Active, not recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=66 --> 6 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Aug 2013; Patient population did not benefit from single agent treatment. Recruiting --> Active, not recruiting
- New trial: ACADHEM: Input of a Multidisciplinary Device to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=30, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
- Enrollment change, Trial withdrawal: Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (clinicaltrials.gov) - Jul 14, 2016
P2, N=0, Withdrawn, Sponsor: University of Medicine and Dentistry of New Jersey
Recruiting --> Active, not recruiting N=38 --> 0 | Suspended --> Withdrawn
- New trial: NOHA-PSY: Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=1592, Completed, Sponsor: Centre Hospitalier Universitaire de N?mes
- | Epogen (epoetin alfa) / Amgen
Trial completion: Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy (clinicaltrials.gov) - Jul 11, 2016
P3, N=344, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=38 --> 0 | Suspended --> Withdrawn No longer recruiting --> Completed
- | Trial completion, Metastases: Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss (clinicaltrials.gov) - Jul 11, 2016
P1/2, N=63, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed No longer recruiting --> Completed
- New trial: Effectiveness of the Myofascial Therapy in the Hemophilic Arthropathy of Ankle (clinicaltrials.gov) - Jul 7, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: Real Fundación Victoria Eugenia
- New trial: Educational Physiotherapy in Haemophilia (clinicaltrials.gov) - Jul 7, 2016
P=N/A, N=20, Completed, Sponsor: Real Fundación Victoria Eugenia
- melphalan / Generic mfg.
Enrollment open: Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation (clinicaltrials.gov) - Jul 7, 2016
P2, N=24, Recruiting, Sponsor: Medical College of Wisconsin
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- | ondansetron / Generic mfg.
Trial completion, Metastases: Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment (clinicaltrials.gov) - Jul 4, 2016
P3, N=100, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New trial: PREDUSED: Patient Education Program and Ehlers-Danlos Syndrome (clinicaltrials.gov) - Jun 29, 2016
P=N/A, N=28, Completed, Sponsor: Hospices Civils de Lyon
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=82, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage (clinicaltrials.gov) - Jun 28, 2016
P=N/A, N=32, Completed, Sponsor: Tampere University Hospital
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016
- || MRX34 / Synlogic
Trial primary completion date: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (clinicaltrials.gov) - Jun 23, 2016
P1, N=200, Recruiting, Sponsor: Mirna Therapeutics, Inc.
Recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016 Trial primary completion date: Dec 2016 --> Mar 2017
- Trial completion, Trial primary completion date: Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells (clinicaltrials.gov) - Jun 23, 2016
P1/2, N=25, Completed, Sponsor: Children's Hospital Los Angeles
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015
- bortezomib / Generic mfg.
Trial primary completion date: Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients (clinicaltrials.gov) - Jun 23, 2016
P2, N=10, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2015 Trial primary completion date: Jul 2016 --> Jul 2017
- | Xofigo (radium Ra-223 dichloride) / Bayer
Phase classification, Combination therapy: Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma (clinicaltrials.gov) - Jun 22, 2016
P1b/2, N=226, Not yet recruiting, Sponsor: Bayer
Trial primary completion date: Jul 2016 --> Jul 2017 Phase classification: P1/2 --> P1b/2
- lenalidomide / Generic mfg.
Trial completion, Enrollment change: Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma (clinicaltrials.gov) - Jun 21, 2016
P1/2, N=6, Completed, Sponsor: Yale University
Phase classification: P1/2 --> P1b/2 Recruiting --> Completed | N=36 --> 6
- Enrollment change, Trial termination: Markers of Defective Membrane Remodelling in Scott-like Syndromes (clinicaltrials.gov) - Jun 19, 2016
P=N/A, N=29, Terminated, Sponsor: University Hospital, Strasbourg, France
Recruiting --> Completed | N=36 --> 6 N=125 --> 29 | Recruiting --> Terminated
- New trial: MCSF-MYELOME: Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=200, Recruiting, Sponsor: Centre Hospitalier Universitaire, Amiens
- ||||| Farydak (panobinostat) / Secura Bio
Clinical: Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat (clinicaltrials.gov) - Jun 16, 2016
P1/2, N=85, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Trial initiation date: Hepatitis Delta Infections in Hemophiliacs (clinicaltrials.gov) - Jun 16, 2016
P=N/A, N=61, Completed, Sponsor: University of North Carolina, Chapel Hill
N=125 --> 29 | Recruiting --> Terminated Initiation date: Sep 1986 --> Sep 1987
- TevaGrastim (filgrastim biosimilar) / Nippon Kayaku, Teva, Mozobil (plerixafor) / Sanofi
Enrollment closed, Combination therapy, Head-to-Head: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 16, 2016
P2, N=100, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Sep 1986 --> Sep 1987 Recruiting --> Active, not recruiting
- Innohep (tinzaparin) / LEO Pharma
Trial primary completion date: METRO B: Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer (clinicaltrials.gov) - Jun 15, 2016
P2, N=24, Recruiting, Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Jun 2017
- Trial primary completion date: MBD: Standardisation of Investigations of Mild Bleeding Disorders (clinicaltrials.gov) - Jun 14, 2016
P=N/A, N=300, Active, not recruiting, Sponsor: University Hospital, Geneva
Trial primary completion date: Oct 2016 --> Jun 2017 Trial primary completion date: Apr 2016 --> Jul 2016
- Enrollment open, Trial primary completion date: PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism (clinicaltrials.gov) - Jun 13, 2016
P=N/A, N=100, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Trial primary completion date: Apr 2016 --> Jul 2016 Withdrawn --> Recruiting | Trial primary completion date: Sep 2014 --> Sep 2017
- ||||| Zolinza (vorinostat) / Merck (MSD)
Clinical: Myeloma XI: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients (clinicaltrials.gov) - Jun 13, 2016
P3, N=4420, Active, not recruiting, Sponsor: University of Leeds
Withdrawn --> Recruiting | Trial primary completion date: Sep 2014 --> Sep 2017 Recruiting --> Active, not recruiting | N=1970 --> 4420
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Enrollment closed: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jun 11, 2016
P1/2, N=10, Active, not recruiting, Sponsor: Adaptimmune
Recruiting --> Active, not recruiting | N=1970 --> 4420 Recruiting --> Active, not recruiting
- || Clinical data, Enrollment closed, HEOR: HAMLET: 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=72, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- albumin-bound paclitaxel / Generic mfg.
Enrollment closed, Trial primary completion date: Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 10, 2016
P2, N=13, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | Trial primary completion date: Sep 2015 --> Sep 2016